Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Innate Pharma S.A. (EPA:IPH) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The revenue forecast for this year has experienced a facelift, with analysts now much more optimistic on its sales pipeline.

Following the upgrade, the most recent consensus for Innate Pharma from its six analysts is for revenues of €40m in 2022 which, if met, would be a major 64% increase on its sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of €34m in 2022. It looks like there's been a clear increase in optimism around Innate Pharma, given the decent improvement in revenue forecasts.

View our latest analysis for Innate Pharma

Of course, another way to look at these forecasts is to place them into context against the industry itself. For example, we noticed that Innate Pharma's rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 64% growth to the end of 2022 on an annualised basis. That is well above its historical decline of 1.3% a year over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 28% annually. Not only are Innate Pharma's revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.

The Bottom Line

The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. The analysts also expect revenues to grow faster than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at Innate Pharma.

Want to learn more? We have analyst estimates for Innate Pharma going out to 2024, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.